Crescendo Biologics has appointed Dr Peter Pack as CEO who will help to oversee the company’s new strategy.
Crescendo is now shifting its focus to oncology with novel VH-based checkpoint modulators and humabody drug conjugate (HDC) therapeutics.
Dr Pack joins with over 23 years of corporate experience in the life science industry. He has also previously served on the board of Signature Diagnostics AG before its sale to Roche in February 2015.
His appointment is representative of Crescendo expanding its oncology pipeline by targeting a range of cancer indications where humabodies have the potential to deliver high-value treatments to patients where there is an unmet medical need.
He said: “The transition to a product-oriented oncology therapeutics company is a pivotal moment in Crescendo’s corporate development. In my view Crescendo’s in vivo maturation technology for 100% human VHs with excellent affinities, expression yields and plug and play options is superior to anything that has been done before.
“We plan to advance the development of new and innovative therapeutics compounds in the area of oncology including immune-oncology, the new primary focus of the work at Crescendo. We intend to expand rapidly our internal oncology programmes on checkpoint modulators and HDCs, which are a novel alternative to antibody drug conjugates.”